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Abstract
Subclinical hypothyroidism (SH) is a condition characterized by a mild persistent thyroid failure. The main cause is
represented by autoimmune thyroiditis, but mutations in genes encoding proteins involved in TSH pathway are
thought to be responsible for SH, particularly in cases arising in familial settings. Patients with the syndrome of TSH
unresponsiveness may have compensated or overt hypothyroidism with a wide spectrum of clinical and
morphological alterations depending on the degree of impairment of TSH-receptor (TSH-R) function. We describe
the case of two brothers with non autoimmune SH carrying the same heterozygous mutation in the extracellular
domain of TSH-R and presenting with different clinical, biochemical and morphological features. The first one had
only a slight persistent elevation of TSH, a normal thyroid ultrasound and did never require l- thyroxine (L-T4)
replacement treatment. The second one had a neonatal persistent moderate TSH levels increase associated with a
thyroid gland hypoplasia and was treated with L-T4 since the first months of life.
These two cases support the recent association of TSH-R mutations inheritance as an autosomal dominant pattern
with variable expressivity and suggest that the decision to start replacement therapy in patients with persistent SH
due to TSH resistance should be individualized.
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Background
Subclinical hypothyroidism (SH) is a biochemical condition
characterized by serum levels of TSH above the statistically
defined upper limit of reference range, with normal
concentrations of thyroid hormones and without severe
clinical features of hypothyroidism [1]. The prevalence has
been reported to be between 4 and 20% of the adult popu-
lation [2] and about 1.7% in US children [3]. However, in
childhood it seems to be a benign remitting condition with
a low risk of progression to overt hypothyroidism [1,4-8].
During neonatal period, a slight increase in TSH levels with
normal thyroid hormone may be transient and sometimes
be the cause of a false positive at neonatal screening for
congenital hypothyroidism (CH) [9]. However, in other
cases it may also be the expression of a mild persistent
thyroid failure due to genetic abnormalities of thyroid
structure or function. The most frequent cause of persistent
SH in childhood is represented by autoimmune thyroiditis.
However, iodine deficiency, obesity, non-thyroidal chronic
diseases or inherited syndromes may also be responsible for
mild increase of TSH levels. When no overt causes of slight
TSH increase are detectable the condition is defined as
idiopathic SH [10]. Mutations in genes encoding proteins
involved in TSH pathway are thought to be responsible for
some cases of idiopathic SH, particularly in cases arising in
familial settings [11,12]. TSH exerts its activity by binding
to the extracellular domain of TSH receptor (TSH-R).
TSH-R is a member of the G protein-coupled receptor
family that also includes calcitonin and PTH receptors [13].
It mediates the effects of TSH in thyroid development,
growth, and thyroid hormone synthesis. Here we describe
the case of two brothers with non autoimmune SH carrying
the same TSH-R mutation and presenting with different
clinical, biochemical and morphological features.* Correspondence: salerno@unina.it
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Case presentation
Patient 1 was a young boy admitted to our Pediatric
Endocrinology Unit at the age of 8-years for the finding
of isolated hyperthyreotropinemia. He was the first child
of healthy unrelated parents. Two blood samples
performed three months apart showed a slight increase
in TSH levels (TSH: 8 μU/ml, normal range: 0.5-4.5)
with normal FT4 concentration (FT4 1.2 ng/dl, normal
range: 0.7-1.6). The neonatal history was normal, he was
not affected by any chronic disease, and was not taking
any drugs potentially interfering with thyroid function.
The reason for thyroid function screening was the
familiarity for thyroid diseases. In fact, the younger
brother was affected by CH and was treated with L-T4
since he was 4-months-old. The physical examination
was normal, no signs or symptoms of hypothyroidism
goiter included were detectable. Auxological parameters
were normal, both weight and height being between
50th-75th percentile; height was appropriate to the
genetic familial target. Autoimmune thyroiditis, morpho-
logical anomalies of thyroid gland, iodine deficiency and
pseudohypoparathyroidism, were excluded by clinical,
biochemical and ultrasound evaluation. He was not
treated with L-T4 due to the slight elevation of TSH
(ranging always between 4.5 and 10 μU/ml) and was
closely monitored with clinical and laboratory examina-
tions. At the age of 10 years, because of the persistence of
SH and the familiarity for thyroid diseases, molecular
analysis for TSH-R was performed. Direct sequencing of
the extracellular and transmembrane-coding regions of the
TSH-R showed an heterozygous missense mutation (CGG
to CAG) in the exon 4 corresponding to an arginine to
glutamine change at codon 109 (R109Q) in the extracellular
domain of the receptor. The patient is now 18 years old.
During the follow-up, despite a persistent slight elevation of
TSH, he never required L-T4 replacement therapy. He
always presented a normal growth and bone maturation.
Puberty began and progressed regularly and the evaluation
of intellectual outcome at the age of 16 years was normal
with an intellectual quotient (IQ) of 108.
Patient 2, the younger brother of patient 1, was re-
ferred to our Unit at the age of 8 years for CH. The
diagnosis of CH was performed on the basis of persistent
moderate hyperthyreotropinemia (TSH 12–15 μU/ml)
with low-normal values of FT4 (FT4 0.8 ng/dl; normal
values 0.7-1.7), and a mild gland hypoplasia at thyroid
ultrasound, incidentally discovered during a laboratory
evaluation for growth retardation. The treatment with
L-T4 was started at the age of 4 months with an initial
dose of 6 μg/kg/day. Due to the finding of a TSH-R mu-
tation in the older brother, we decided to re-evaluate the
diagnosis of CH. The TSH-R molecular analysis showed
the same heterozygous missense mutation of the
brother, thus we decided to stop L-T4 therapy.
However, TSH levels raised in a month over 10 μU/ml
and persisted elevated in the following 3 measure-
ments, ranging between 13 and 18 μU/ml. Moreover, he
reported clinical symptoms of hypothyroidism such as
fatigue, mood changes and impaired concentration in
addition to significant weight gain. Therefore, L-T4 ther-
apy was promptly re-started. During the follow-up he pre-
sented a normal growth and bone maturation. The
puberty began and progressed regularly but the evaluation
of IQ at the age of 16 years was slightly low (IQ 80).
Discussion
Subclinical hypothyroidism is a relatively common
condition characterized by a mild thyroid failure. It can
occur at any age from neonatal period to adulthood in
both transient or persistent form. Newborns with SH
may have a transient impairment of thyroid function due
to environmental or mother-derived causes, but they can
also have genetic abnormalities of thyroid structure and
function. During childhood the main cause of SH is
generally represented by autoimmune SH, other known
causes being mild developmental thyroid abnormalities,
iodine deficiency, obesity, non-thyroidal chronic diseases
or inherited syndromes and mutations in the TSH-R
gene. Loss of function mutations in genes encoding
proteins involved in the TSH pathway, TSH-R anomalies
or alterations in the proteins involved in the signaling
pathway downstream the receptor, have been widely
demonstrated to be responsible of SH [11,14-18]. In a
recent study, Rapa et al. evaluated the clinical characteris-
tics and TSH-R gene variation in a series of children with
slight to moderate elevation of TSH with normal thyroid
hormone due to non autoimmune SH. Non-synonymous
mutations of TSH-R gene or polymorphisms were found in
21.5% of cases [14]. The prevalence of a positive family
history of thyroid diseases was two-fold higher in patients
with mutations than in those with no mutations. An even
higher prevalence of mutation in the TSH-R gene (29%)
was detected by Nicoletti et al. [11]. Eleven mutations of
TSH-R gene were identified in a cohort of 38 children and
adolescents with non-autoimmune SH. In our first patient
the main causes of persistent SH were ruled out at first
examination. The diagnosis of partial resistance to TSH
was suggested by the familiar history of thyroid diseases.
Although both sibs were carrying the same mutation,
they had completely different clinical phenotype. The
first boy had a slight persistent increase of TSH (less than
10 μU/ml), normal thyroid ultrasound and did not show
any signs or symptoms of mild hypothyroidism requiring
L-T4 treatment. Conversely, the younger brother presented
a moderate increase of TSH with serum levels persistently
above 10 μU/ml with low normal serum FT4 concentra-
tions, morphological thyroid anomalies with a mild thyroid
hypoplasia. He needed to be treated in early infancy and
Cerbone et al. Italian Journal of Pediatrics 2013, 39:5 Page 2 of 5
http://www.ijponline.net/content/39/1/5
relapsed when treatment was withdrawn. Indeed, even with
a mild increase in TSH levels, he presented slight
symptoms of hypothyroidism that prompted us to restore
L-T4 treatment. Despite treatment, his IQ was slightly low
thus raising the question on whether the delay in starting
replacement treatment or a low initial dose of L-T4 may
have influenced the suboptimal IQ outcome [19]. Pituitary
TSH is critical for thyroid development and function and
exerts its activity by binding to the extracellular domain of
TSH-R, a G protein-coupled seven-transmembrane domain
receptor located in the basolateral membrane of thyroid
follicular cells. The principal biological effects of TSH on
the thyrocite occur by receptor-mediated activation of Gsα
and subsequent generation of intracellular cAMP [20,21].
The human TSH-R gene is located on chromosome 14q31
and encodes a protein of 764 amino acids. The gene is
comprised of 10 exons, with the first nine encoding the
extracellular domain and the large exon 10 encoding the
transmembrane domain and the cytoplasmic tail [14].
Patients with the syndrome of TSH unresponsiveness may
have compensated [17,22-24] or overt hypothyroidism
[25-30] depending on the presence of a partial or
complete TSH resistance. These conditions include a wide
spectrum of biochemical, as well as clinical and morpho-
logical alterations depending on the degree of impairment
of TSH-R function. The metabolic consequences can
range from mild SH to severe CH. TSH is a prerequisite
not only for normal thyroid hormone synthesis but also
for proliferation. Accordingly, the inherited CH in the hyt/
hyt mouse was shown to be caused by homozygosity for a
loss of function mutation of the TSH-R (P556L) leading to
thyroid hypoplasia and severe CH [29]. The mutation
R109Q in the extracellular domain of TSH-xR, found in
our two brothers, was first described by Clifton-Bligh
et al. in a child compound heterozygote for another
missense mutation in the fourth transmembrane segment
of receptor. This child presented with markedly increased
serum TSH concentrations and low normal thyroid
hormone levels identified after a positive result on
neonatal screening for CH, normal thyroid morphology
and treated with L-T4 since 8 weeks of age [17]. Similarly
to our second patient, after the L-T4 withdrawal at the
age of 2 years, he showed a significant increase of TSH
levels that required a resumption of therapy. Moreover,
the R109Q mutation has also been documented in Italian
children with non-autoimmune SH [11,14]. In particular,
the two siblings reported by Nicoletti et al. [11], carrying
the same heterozygous R109Q loss of function mutation
found in our two patients, had a mild phenotype charac-
terized by a slightly increase in serum TSH, normal
thyroid gland at ultrasound and no clinical features of
thyroid dysfunction. Similarly to our first patient they do
not need treatment, thus highlighting the wide phenotypic
variability in children with SH due to the same TSH-R
mutation. In the earlier studies in which only probands
with large TSH elevations were screened for mutations,
the disease was linked to homozygous or compound
heterozygous mutations and was described to follow a
recessive pattern of inheritance [17,18,20-29]. More
recently inheritance of TSH-R resistance has been
associated with an autosomal dominant pattern without
evidence for incomplete penetrance, but with variable
expressivity. Several families have been described with
dominant transmission of partial TSH resistance due to
heterozygous inactivating mutations in TSH-R [30,31].
The recent finding that TSH-R, like other G protein-
coupled receptors, can oligomerize in living cells led to
the hypothesis that the formation of complexes between
wild-type and mutant receptors may be responsible for
partial TSH resistance in patients with heterozygous
TSH-R mutations [31]. The clinical heterogeneity in our
2 patients carrying the same mutation, is not surprising
as other monogenic diseases have been already shown
to have a different phenotype despite the same causing
mutation [32-36]. For most of these conditions, molecular
basis of this heterogeneity are not well delineated. Disease
modifying genes, variation in environmental exposures, as
well as system dynamics may come into play in modulating
clinical expression of the disease. If the treatment should
be indicated or not in patients with only slight elevation of
TSH due to TSH-R resistance is controversial. In fact, the
elevation of circulating TSH would represent the compen-
satory mechanism allowing gland development and the
maintenance of a normal thyroid hormone secretion in the
presence of partial refractoriness to TSH action. Currently,
there is no evidence that children with only slight increase
in TSH levels (less than 10 μU/ml) and normal FT4 con-
centrations suffer any clinical or neurological abnormality
that would be eventually restored to normal by L-T4
treatment [6,8]. Therefore the decision to treat with L-T4
SH still represents a clinical dilemma.
Conclusions
Patients with persistent non autoimmune hyperthyreotropi-
nemia should be investigated for TSH-R gene, in particular
in cases arising in familial settings, even though the major-
ity of patients with an heterozygous TSH-R loss of function
mutation have only mild SH generally not requiring any
treatment. However, it should be mentioned that some
cases may have a more severe clinical presentation with the
need of lifelong treatment. Currently is not possible to pre-
dict the clinical presentation and the evolution of these
patients based on genetic features.
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